GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Net Income From Continuing Operations

Nanopharmaceutics (Nanopharmaceutics) Net Income From Continuing Operations : $-1.12 Mil (TTM As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Nanopharmaceutics's net income from continuing operations for the three months ended in Sep. 2018 was $-0.08 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2018 was $-1.12 Mil.

Nanopharmaceutics Net Income From Continuing Operations Historical Data

The historical data trend for Nanopharmaceutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics Net Income From Continuing Operations Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
Net Income From Continuing Operations
- -0.91 -1.22

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.10 -0.60 -0.23 -0.21 -0.08

Nanopharmaceutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics (Nanopharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Net Income From Continuing Operations
Comparable Companies
MIII TSE:5363 TSE:7721 TSE:5821 TSX:AEF SDOIA DFM:GGICO SAU:2120 ABWN COL:RICH.N0000 CNAC MIL:SPRT XSGO:QUEMCHI TSE:3353 COL:VONE.N0000 XPAE:APIC MIL:CRS ELEC ATH:MIG XCNQ:MARI
Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Website
https://www.nanopharmaceutics.com
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.